Christie introduces groundbreaking far-UVC light fixture with patented Care222 technology for UV disinfection that may be used around people. <\/strong>Christie CounterAct aims to reduce pathogens in commercial indoor venues<\/strong> <\/strong><\/p>\n Christie\u00ae<\/strong><\/a> is pleased to announce the launch of the Christie\u00ae CounterAct<\/strong><\/a>\u2122 line of commercial UV disinfection products with patented Care222\u00ae far-UVC light technology for cinemas, theme parks, museums, sports complexes and other indoor spaces. Unlike comparable products, the Christie fixture uses Ushio\u2019s patented narrowband filtered Care222 excimer lamps that emit far-UVC 222nm light – the only<\/strong> UV technologyshown to continuously and significantly reduce pathogens, like coronaviruses, that may also be used while people are present, when used in accordance with specified parameters. Mass production of the new Christie CounterAct<\/strong> fixture starts in January 2021.<\/strong><\/p>\n Developed by Christie\u2019s parent company, Ushio Inc., based on technology licensed from Columbia University, the revolutionary Care222 far-UVC, mercury-free excimer lamp\u2014highlighted in FORTUNE magazine\u2019s annual Change the World list1<\/sup> in 2020, includes a proprietary short pass filter that prevents the emission of longer wavelengths of UV light (230nm and higher) that are capable of penetrating human skin and eyes, an especially important feature that other 222nm and far-UVC products do not have.<\/p>\n Christie CounterAct introduces an added layer of defense against pathogens in indoor venues when guests and staff are present<\/strong> The background on UV light<\/strong>
\nChristie CounterAct is a line of fixtures that are simple to control remotely and can be installed on ceilings as easily as a commercial lighting fixture. It is well suited for use across a wide range of occupied, commercial areas such as entertainment venues, including lobbies, auditoriums, and restrooms, as well as other indoor spaces. Our first Christie CounterAct fixture contains two Care222 excimer far-UVC lamps that significantly reduce pathogens on surfaces of any indoor space. The fixture, with fast instant on\/off at full output power and its Care222 technology lamps, has been shown effective at reducing pathogens in laboratory tests2<\/sup>. And unlike other UV technology, these fixtures with patented Care222 lamps may be used when people are present.<\/p>\n
\nIt has been known for many years that UV light is a highly effective disinfectant that can reduce pathogens in indoor spaces. Businesses and other institutions have long used germicidal UVC light to stop the spread of viruses. The main drawback with most UVC technology is that it uses a 254nm wavelength that can penetrate human skin and eyes, which means these germicidal lights can only be used when people are not present or while they\u2019re wearing personal protective equipment (PPE) that protects the eyes and skin. These shortcomings constrain how these devices must be operated and limit their widespread use in occupied indoor spaces. <\/p>\n